| Revenue growth | H2FY26 revenue up 23.1% YoY to ₹41.6 Cr. |
|---|---|
| Margins | EBITDA margin surged 2625 bps HoH to 26.32% in H2. |
| Demand visibility | Strong sales momentum returned in H2 with restored customer demand. |
| Management confidence | High; cited decisive rebound after intentional H1 credit tightening. |
Growth
H2FY26 revenue grew 23.1% YoY and 64.4% HoH. FY26 annual revenue reached ₹66.9 Cr, up 8.6% YoY.
Outlook
Targeting 500 standardized Xelix clinics by expanding into skin and body aesthetics verticals from a hair-first focus.
Risks
Historically high inventory and credit-driven sales softened H1 performance; regulatory shifts during private-to-public conversion.
Earnings Call filed with NSE, NSE: AAKAAR. Summary written with AI assistance from the document.
Aakaar Medical Technologies Ltd: key numbers
- Share price
- ₹70.00
- Market cap
- ₹99.21 Cr
- Revenue (annual)
- ₹66.96 Cr
- Net profit (annual)
- ₹6.64 Cr
- P/E (TTM)
- 14.9×Sector 57.8×
- Promoter holding
- 67.05%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aakaar Medical Technologies Ltd
All →Aakaar Medical Technologies Earnings Call: Key Takeaways
Aakaar Medical Technologies reported FY26 revenue of INR 67 Cr (up 8.6%) and PAT of INR 6.63 Cr (up 10%). The company is shifting towards an asset-light DODO clinic model via its Xelix platform.
Aakaar Medical Technologies Earnings Call: Key Takeaways
Aakaar Medical Technologies reported strong FY26 recovery with ₹66.9cr revenue and record H2 profitability driven by high-margin product launches and improved debtor discipline.
Aakaar Medical Technologies H2 FY26 Results: Net Profit ₹7.4 Cr, Up 32.1% YoY
Aakaar Medical Technologies Ltd reported revenue from operations of ₹41.6 Cr (+22.7% YoY) and net profit of ₹7.4 Cr (+32.1% YoY) for H2 FY26.
- Key figure
- Net profit ₹7.4 Cr · +32.1% YoY